Listar por autor "Jiménez-Rodríguez, Begoña"
Mostrando ítems 1-7 de 7
-
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
Jiménez-Rodríguez, Begoña; Alba-Bernal, Alfonso; López-López, Esperanza; Quirós-Ortega, María Elena; Carbajosa, Guillermo; Garrido-Aranda, Alicia; Álvarez-Pérez, Martína
; Godoy-Ortiz, Ana; Queipo-Ortuño, María Isabel; Vicioso-Recio, Luis Prudencio; Díaz-Córdoba, Gema; Roldán-Díaz, María Dunia; Velasco-Suelto, Jesús; Hernando Melia, Cristina; Bermejo, Begoña; Julve-Parreño, Ana; Lluch, Ana; Pascual, Javier; Comino-Méndez, Iñaki; Alba-Conejo, Emilio[et al.] (IOAP-MDPI, 2022-12-21)
Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating ... -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
Efecto de la quimioterapia neoadyuvante en la variación de receptores hormonales, Her2 y Ki67 en pacientes con cáncer de mama
Álvarez-Pérez, Martína; Lavado-Fernández, Ana Isabel; Pérez-Villa, Lidia; Lozano, María José; Jiménez-Rodríguez, Begoña; De Luque, Vanessa; Jiménez-Vista, Álvaro; Ventura, Carmen; Jiménez-Fernández, Ana; Rodrigo-Fernández, Isabel; Ramírez-Tortosa, César; Ribelles, Nuria; Alba-Conejo, Emilio; Vicioso-Recio, Luis Prudencio[et al.] (2016-03-02)
Introducción:Existe controversia respecto al impacto de la quimioterapia en la expresión de marcadores inmunohistoquímicos del cáncer de mama, ya que pueden existir cambios en los marcadores tumorales entre las biopsias ... -
Estudio de factores predictivos de respuesta patológica a quimioterapia neoadyuvante en el cáncer de mama receptores hormonales positivos HER2 negativo
Lavado-Fernández, Ana Isabel; Álvarez-Pérez, Martína; Prieto Cuadra, Juan Daniel; Jiménez-Rodríguez, Begoña; Lozano, María José; De Luque, Vanessa; Jiménez-Vista, Álvaro; Ventura, Carmen; Jiménez-Fernández, Ana; Rodrigo, Isabel; Ramírez, César; Cano, Tatiana; González-Zafra, Virginia; Pérez-Villa, Lidia; Gallego-Domínguez, Elena María; Ortega-Jiménez, María Victoria; Arranz-Salas, Isabel María; Ribelles, Nuria; Alba-Conejo, Emilio; Vicioso-Recio, Luis Prudencio[et al.] (2015-07-02)
La quimioterapia neoadyuvante (QTN) se utiliza cada vez más para conseguir una reducción tumoral que permita una cirugía conservadora y, mediante el grado de respuesta patológica tumoral, determinar el pronóstico de las ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Pajares, Bella; Vicioso-Recio, Luis Prudencio; Jiménez-Rodríguez, Begoña; De Luque, Vanessa; Franco, Leónardo; Gallego-Domínguez, Elena María; Márquez, Antonia; Álvarez, Martina; Sánchez-Muñoz, Alfonso; Pérez-Rivas, Luis G.; Alba-Conejo, Emilio; Ribelles, Nuria[et al.] (BMC, 2013-10-22)
Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Results: Luminal A displayed ... -
Targeted therapies in the treatment of germ cell tumors: The need for new approaches against “orphan” tumors
Sánchez-Muñoz, Alfonso; Jiménez-Rodríguez, Begoña; Navarro-Pérez, Víctor; Medina-Rodríguez, Laura; Llácer, Casilda; Vicioso-Recio, Luis Prudencio; Machuca, Javier; Alba-Conejo, Emilio[et al.] (Elsevier Ireland Ltd, 2012)
Germ cell tumors (GCTs) are a heterogeneous group of tumors that are highly clinically relevant to oncologists. GCTs are generally highly sensitive to cisplatin-based chemotherapy and represent a model for curable neoplasms. ...